Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Satellos Bioscience Inc (MSCLF)

Satellos Bioscience Inc (MSCLF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 66,924
  • Shares Outstanding, K 113,431
  • Annual Sales, $ 0 K
  • Annual Income, $ -11,770 K
  • EBIT $ -19 M
  • EBITDA $ -19 M
  • 60-Month Beta 1.77
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.60
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.18
  • Most Recent Earnings $-0.06 on 11/13/24
  • Next Earnings Date 11/27/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4940 +25.51%
on 12/03/24
0.9350 -33.69%
on 12/11/24
+0.0900 (+16.98%)
since 11/26/24
3-Month
0.3351 +85.02%
on 09/30/24
0.9350 -33.69%
on 12/11/24
+0.2320 (+59.79%)
since 09/25/24
52-Week
0.2974 +108.47%
on 05/06/24
0.9350 -33.69%
on 12/11/24
+0.3013 (+94.54%)
since 12/22/23

Most Recent Stories

More News
Bloom Burton & Co. Inc. Announces Changes to Holdings in Satellos Bioscience Inc.

Toronto, Ontario--(Newsfile Corp. - December 20, 2024) - Bloom Burton & Co. Inc. (Bloom Burton) announces that, today, it acquired 1,692,250 common shares (Shares) of Satellos Bioscience Inc. (Corporation)...

MSCLF : 0.6200 (+5.08%)
MSCL.TO : 0.87 (-2.25%)
Satellos to Participate in the Cantor Fitzgerald Global Healthcare Conference 2023

Toronto, Ontario--(Newsfile Corp. - September 20, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic...

MSCLF : 0.6200 (+5.08%)
MSCL.VN : 0.560 (+1.82%)
Satellos Bioscience Enters Into an Agreement with ICP Securities Inc. to Provide Market Making Services

Toronto, Ontario--(Newsfile Corp. - September 7, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic...

MSCLF : 0.6200 (+5.08%)
MSCL.VN : 0.560 (+1.82%)
Satellos Expands Leadership Team with New CFO Appointment

Elizabeth Williams, CPA, CA, joins as CFO, bringing extensive expertise leading corporate finance and strategy for public biotech companies listed on Nasdaq and TSX.Current CFO, Warren Whitehead, CPA,...

MSCLF : 0.6200 (+5.08%)
MSCL.VN : 0.560 (+1.82%)
Satellos Bioscience Announces Q2 2023 Financial Results and Operational Highlights

$48.7 million in cash and cash equivalents at June 30, 2023, providing expected runway to advance Company's development candidate ("DC") through Phase I clinical development in healthy human volunteers...

MSCLF : 0.6200 (+5.08%)
MSCL.VN : 0.560 (+1.82%)
Satellos Bioscience Receives Orphan Drug Designation from the U.S. FDA for SAT-3153, a First-in-Class Small Molecule Therapeutic for Duchenne Muscular Dystrophy

Company also recently received Rare Pediatric Disease Designation from the FDA for SAT-3153 for the treatment of pediatric patients with DuchenneToronto, Ontario--(Newsfile Corp. - August 2, 2023) - Satellos...

MSCLF : 0.6200 (+5.08%)
MSCL.VN : 0.560 (+1.82%)
Satellos Bioscience Announces Results from Its Annual General Meeting of Shareholders and Adoption of Amendments to Stock Option Plan

Toronto, Ontario--(Newsfile Corp. - June 30, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the...

MSCLF : 0.6200 (+5.08%)
MSCL.VN : 0.560 (+1.82%)
Satellos Bioscience Announces Appointment of Chief Medical Officer

Dr. Alan K. Jacobs joins Satellos as CMO on June 7th, 2023Toronto, Ontario--(Newsfile Corp. - June 7, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine...

MSCLF : 0.6200 (+5.08%)
MSCL.VN : 0.560 (+1.82%)
Satellos Bioscience Announces Grant of Stock Options

Toronto, Ontario--(Newsfile Corp. - June 1, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the...

MSCLF : 0.6200 (+5.08%)
MSCL.VN : 0.560 (+1.82%)
Satellos Bioscience Announces 2023 Q1 Financial Results and Operational Highlights

- $55 million equity financing closed- Resourced to advance lead drug candidate into clinical trialsToronto, Ontario--(Newsfile Corp. - May 30, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos"...

MSCLF : 0.6200 (+5.08%)
MSCL.VN : 0.560 (+1.82%)

Business Summary

Satellos Bioscience Inc. is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company's lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience...

See More

Key Turning Points

3rd Resistance Point 0.6608
2nd Resistance Point 0.6467
1st Resistance Point 0.6333
Last Price 0.6200
1st Support Level 0.6058
2nd Support Level 0.5917
3rd Support Level 0.5783

See More

52-Week High 0.9350
Fibonacci 61.8% 0.6914
Last Price 0.6200
Fibonacci 50% 0.6162
Fibonacci 38.2% 0.5410
52-Week Low 0.2974

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar